| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Whales with a lot of money to spend have taken a noticeably bearish stance on Humacyte.
Looking at options history for Humacyte (NASDAQ:HUMA) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 62% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $131,821 and 6, calls, for a total amount of $520,230.
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $5.0 to $7.5 for Humacyte over the last 3 months.
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Humacyte's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Humacyte's whale activity within a strike price range from $5.0 to $7.5 in the last 30 days.
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| HUMA | CALL | SWEEP | BULLISH | 12/20/24 | $3.3 | $2.95 | $3.3 | $5.00 | $204.6K | 3.3K | 631 |
| HUMA | CALL | TRADE | BEARISH | 09/20/24 | $3.0 | $2.65 | $2.75 | $5.00 | $192.5K | 3.7K | 702 |
| HUMA | PUT | SWEEP | BULLISH | 09/20/24 | $0.8 | $0.2 | $0.3 | $5.00 | $93.8K | 3.3K | 3.1K |
| HUMA | PUT | SWEEP | BULLISH | 08/16/24 | $1.1 | $0.95 | $0.95 | $7.50 | $38.0K | 3.0K | 1.1K |
| HUMA | CALL | TRADE | BEARISH | 12/20/24 | $4.0 | $3.0 | $3.3 | $5.00 | $36.6K | 3.3K | 742 |
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
Having examined the options trading patterns of Humacyte, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $13.0.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Humacyte with Benzinga Pro for real-time alerts.
Posted In: HUMA
